全文获取类型
收费全文 | 27593篇 |
免费 | 2192篇 |
国内免费 | 82篇 |
专业分类
耳鼻咽喉 | 212篇 |
儿科学 | 680篇 |
妇产科学 | 614篇 |
基础医学 | 4009篇 |
口腔科学 | 358篇 |
临床医学 | 2824篇 |
内科学 | 5504篇 |
皮肤病学 | 311篇 |
神经病学 | 2561篇 |
特种医学 | 618篇 |
外国民族医学 | 3篇 |
外科学 | 3788篇 |
综合类 | 537篇 |
一般理论 | 42篇 |
预防医学 | 2480篇 |
眼科学 | 884篇 |
药学 | 2293篇 |
中国医学 | 37篇 |
肿瘤学 | 2112篇 |
出版年
2023年 | 171篇 |
2022年 | 220篇 |
2021年 | 609篇 |
2020年 | 385篇 |
2019年 | 620篇 |
2018年 | 622篇 |
2017年 | 483篇 |
2016年 | 583篇 |
2015年 | 681篇 |
2014年 | 961篇 |
2013年 | 1409篇 |
2012年 | 1973篇 |
2011年 | 2083篇 |
2010年 | 1189篇 |
2009年 | 1033篇 |
2008年 | 1725篇 |
2007年 | 1850篇 |
2006年 | 1910篇 |
2005年 | 1904篇 |
2004年 | 1856篇 |
2003年 | 1610篇 |
2002年 | 1500篇 |
2001年 | 231篇 |
2000年 | 189篇 |
1999年 | 254篇 |
1998年 | 340篇 |
1997年 | 288篇 |
1996年 | 270篇 |
1995年 | 254篇 |
1994年 | 205篇 |
1993年 | 212篇 |
1992年 | 153篇 |
1991年 | 130篇 |
1990年 | 109篇 |
1989年 | 101篇 |
1988年 | 107篇 |
1987年 | 94篇 |
1986年 | 87篇 |
1985年 | 95篇 |
1984年 | 102篇 |
1983年 | 102篇 |
1982年 | 132篇 |
1981年 | 126篇 |
1980年 | 95篇 |
1979年 | 59篇 |
1978年 | 62篇 |
1977年 | 64篇 |
1976年 | 58篇 |
1974年 | 55篇 |
1973年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
941.
942.
Damian Kelleher Tristan R. A. Lane Ian J Franklin Alun H Davies 《Lasers in medical science》2014,29(2):493-499
Varicose veins are common and cause extensive morbidity; however, the value of treatment is under-appreciated. Many procedures allow the treatment of varicose veins with minimal cost and extensive literature supporting differing minimally invasive approaches. In this article, we investigate the current literature regarding treatment options, clinical outcome and the cost-benefit economics associated with varicose vein treatment. The practice of defining clinical outcome with quality of life (QOL) assessment is explained to provide valid concepts of treatment success beyond occlusion rates. 相似文献
943.
944.
945.
Duration of Antiresorptive Effects of Low‐Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized,Placebo‐Controlled Trial
下载免费PDF全文
![点击此处可从《Journal of bone and mineral research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Andrew Grey MD Mark Bolland Bobby Mihov Sumwai Wong Anne Horne Greg Gamble Ian R Reid 《Journal of bone and mineral research》2014,29(1):166-172
Annual intravenous administration of 5 mg zoledronate decreases fracture risk, but the optimal dosing regimen for zoledronate has not been determined. We set out to evaluate the antiresorptive effects of a single administration of lower doses of zoledronate. A total of 180 postmenopausal women with osteopenia enrolled in a double‐blind, randomized, placebo‐controlled trial over 2 years at an academic research center. Participants were randomized to a single baseline administration of intravenous zoledronate in doses of 1 mg, 2.5 mg, or 5 mg, or placebo. The primary endpoint was change in bone mineral density(BMD) at the lumbar spine. Secondary endpoints were change in BMD at the proximal femur and total body, and changes in biochemical markers of bone turnover. After 2 years, the change in spine BMD was greater in each of the zoledronate groups than in the placebo group; values are mean (95% confidence interval [CI]) difference versus placebo: zoledronate 1 mg 4.4% [2.7% to 6.1%]; 2.5 mg 5.5% [3.9% to 7.2%]; 5 mg 5.3% [3.8% to 6.7%], p < 0.001 for each dose). Change in BMD at the total hip was greater in each of the zoledronate groups than the placebo group (mean [95% CI] difference versus placebo: zoledronate 1 mg 2.6% [1.5% to 3.7%]; 2.5 mg 4.4% [3.5% to 5.3%]; 5 mg 4.7% [3.7% to 5.7%], p < 0.001 for each dose). Each of the bone turnover markers, β‐C‐terminal telopeptide of type I collagen (β‐CTX) and procollagen type‐I N‐terminal propeptide (P1NP), was lower in each of the 2.5‐mg and 5‐mg zoledronate groups than the placebo group throughout the trial (p < 0.001 versus placebo for each marker for each dose at each time point). For each endpoint, changes were similar in the 2.5‐mg and 5‐mg zoledronate groups, whereas those in the 1‐mg group were smaller than those in the other zoledronate groups. These data demonstrate that single administrations of zoledronate 1 mg or 2.5 mg produce antiresorptive effects that persist for at least 2 years. Trials assessing the antifracture efficacy of intermittent low doses of zoledronate, in particular the 2.5‐mg dose, are justified. © 2014 American Society for Bone and Mineral Research. 相似文献
946.
Melancholia in later life: late and early onset differences in presentation,course, and dementia risk
下载免费PDF全文
![点击此处可从《International journal of geriatric psychiatry》网站下载免费的PDF全文](/ch/ext_images/free.gif)
947.
Ian M. Kronish M.D. M.P.H. Nina Rieckmann Ph.D. Matthew M. Burg Ph.D. Carmela Alcántara Ph.D. Karina W. Davidson Ph.D. 《Annals of behavioral medicine》2014,47(2):158-164
Background
Depression is associated with poor adherence to medications and worse prognosis in patients with acute coronary syndrome (ACS).Purpose
To determine whether cognitive, behavioral, and/or psychosocial vulnerabilities for depression explain the association between depression and medication adherence among ACS patients.Methods
One hundred sixty-nine ACS patients who agreed to have their aspirin adherence measured using an electronic pill bottle for 3 months were enrolled within 1 week of hospitalization. Linear regression was used to determine whether depression vulnerabilities predicted aspirin adherence after adjustment for depressive symptoms, demographics, and comorbidity.Results
Of the depression vulnerabilities, only role transitions (beta?=??3.32; P?=?0.02) and interpersonal conflict (beta -3.78; P?=?0.03) predicted poor adherence. Depression vulnerabilities did not mediate the association between depressive symptoms and medication adherence.Conclusions
Key elements of the psychosocial context preceding the ACS including major role transitions and conflict with close contacts place ACS patients at increased risk for poor medication adherence independent of depressive symptoms. 相似文献948.
L. Alison Phillips Ph.D Michael A. Diefenbach PhD Ian M. Kronish MD Rennie M. Negron MPH Carol R. Horowitz MD 《Annals of behavioral medicine》2014,48(1):7-16
Background
Patients’ medication-related concerns and necessity-beliefs predict adherence. Evaluation of the potentially complex interplay of these two dimensions has been limited because of methods that reduce them to a single dimension (difference scores).Purpose
We use polynomial regression to assess the multidimensional effect of stroke-event survivors’ medication-related concerns and necessity beliefs on their adherence to stroke-prevention medication.Methods
Survivors (n?=?600) rated their concerns, necessity beliefs, and adherence to medication. Confirmatory and exploratory polynomial regression determined the best-fitting multidimensional model.Results
As posited by the necessity-concerns framework (NCF), the greatest and lowest adherence was reported by those necessity weak concerns and strong concerns/weak Necessity-Beliefs, respectively. However, as could not be assessed using a difference-score model, patients with ambivalent beliefs were less adherent than those exhibiting indifference.Conclusions
Polynomial regression allows for assessment of the multidimensional nature of the NCF. Clinicians/Researchers should be aware that concerns and necessity dimensions are not polar opposites. 相似文献949.
Ian H. de Boer Maryam Afkarian Tessa C. Rue Patricia A. Cleary John M. Lachin Mark E. Molitch Michael W. Steffes Wanjie Sun Bernard Zinman 《Journal of the American Society of Nephrology : JASN》2014,25(10):2342-2350
Macroalbuminuria, defined as urine albumin excretion rate (AER)≥300 mg/d, has long been considered a stage of irreversible kidney damage that leads reliably to GFR loss. We examined the long-term renal outcomes of persons with type 1 diabetes who developed incident macroalbuminuria during the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study. One hundred fifty-nine participants developed incident macroalbuminuria and were subsequently followed for a median duration of 9 years (maximum of 25 years). At the time of macroalbuminuria diagnosis, mean (SD) age was 37 (9) years, mean (SD) duration of diabetes was 17 (5) years, median AER was 524 mg/d, and mean (SD) eGFR was 108 (20) ml/min per 1.73 m2. Ten years after macroalbuminuria diagnosis, the cumulative incidence of a sustained reduction in AER to <300 mg/d was 52%, mostly but not entirely under treatment with renin-angiotensin system inhibitors. The cumulative incidence of impaired GFR (sustained eGFR<60 ml/min per 1.73 m2) 10 years after macroalbuminuria diagnosis was 32%, including 16% who developed ESRD. Lower hemoglobin A1c and BP and regression to AER<300 mg/d were associated with reduced risk of developing impaired GFR. In conclusion, people with type 1 diabetes who develop macroalbuminuria are at high risk of progressive kidney disease. However, through at least 10 years of follow-up, AER could often be controlled, and GFR frequently remained in the normal range.Macroalbuminuria, defined as urine albumin excretion rate (AER)≥300 mg/d, has long been considered a stage of irreversible kidney damage that leads reliably to GFR loss.1 In early published type 1 diabetes cohorts, macroalbuminuria was associated with a 15-year cumulative incidence of ESRD as high as 75%.2,3 However, contemporary long-term renal outcomes of macroalbuminuria have not been fully characterized.The Diabetes Control and Complications Trial (DCCT) and its observational follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, present a valuable opportunity to examine macroalbuminuria and its long-term clinical outcomes. In DCCT/EDIC, the onset of macroalbuminuria can be defined with confidence using frequent longitudinal measurements of AER, participants have been followed for up to 25 years after the diagnosis of macroalbuminuria, and outcomes were meticulously recorded using standardized methods. Previous work in this cohort has shown that most cases of impaired GFR are preceded by macroalbuminuria,4 which is associated with a 50-fold higher risk of developing impaired GFR (eGFR<60 ml/min per 1.73 m2).5 Here, we extend these studies by comprehensively evaluating the long-term renal outcomes of incident macroalbuminuria in the DCCT/EDIC cohort and examining the risk factors for its progression to impaired GFR. 相似文献
950.